This paper identifies mutations that improve the production and efficacy of SARS-CoV-2 Spike proteins, protecting animal models from the Beta variant.

bioRxiv · Jul 7, 2023Immunology

A Novel Monoclonal Antibody Targeting a Large Surface of the Receptor Binding Motif Shows Pan-neutralizing SARS-CoV-2 Activity Including BQ.1.1 Variant

L. de Campos-Mata, B. Trinite, A. Modrego, S. Tejedor Vaquero, E. Pradenas, N. Rodrigo Melero, D. Carlero, S. Marfil, A. Pons-Grifols, M. T. Bueno-Carrasco, C. Santiago, F. Tarres-Freixas, V. Urrea, N. Izquierdo, E. Riveira-Munoz, , G. Magri

This study characterizes a new monoclonal antibody, 17T2, that broadly neutralizes SARS-CoV-2 variants, including BQ.1.1, and shows in vivo prophylactic activity against Omicron BA.1.1.

bioRxiv · Jan 20, 2023 · PreprintImmunology

Previous SARS-CoV-2 infection increases B.1.1.7 cross-neutralization by vaccinated individuals.

B. Trinite, E. Pradenas, S. Marfil, C. Rovirosa, V. Urrea, F. Tarres-Freixas, R. Ortiz, J. Vergara-Alert, J. Segales, V. Guallar, A. Lepore, N. Izquierdo-Useros, G. Trujillo, J. Trape, C. Gonzalez-Fernandez, , J. Blanco

The paper assesses how prior SARS-CoV-2 infection affects B.1.1.7 cross-neutralization in vaccinated individuals, finding that previously infected individuals show equivalent neutralization against B.1.1.7 compared to the Wuhan strain.

bioRxiv · Mar 5, 2021Immunology

Stable neutralizing antibody levels six months after mild and severe COVID-19 episode

E. Pradenas, B. Trinite, V. Urrea, S. Marfil, C. Avila-Nieto, M. L. Rodriguez de la Concepcion, F. Tarres-Freixas, S. Perez-Yanes, C. Rovirosa, E. Ainsua-Enrich, J. Rodon, J. Vergara-Alert, J. Sagales, V. Guallar, A. Valencia, , J. Blanco

This study tracks neutralizing antibody levels in COVID-19 patients up to six months post-infection, finding persistent activity in mild cases and a slower decline in hospitalized individuals.

bioRxiv · Nov 22, 2020Immunology